Paratek Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences
September 01 2016 - 8:00AM
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that
the company will participate in two upcoming investor conferences.
Paratek is a biopharmaceutical company focused on the development
and commercialization of innovative therapies based upon
tetracycline chemistry. President and Chief Medical Officer,
Evan Loh, MD, will present at the following events:
- Baird’s 2016 Global Healthcare Conference on
Wednesday, September 7 from 1:25 to 1:55 p.m. at the New York
Palace Hotel. To access the live webcast of Paratek's Baird
presentation, please visit http://wsw.com/webcast/baird46/prtk. A
replay of the webcast can be accessed for up to 90 days following
the live presentation.
- Ladenburg Thalmann 2nd Annual Healthcare
Conference on Tuesday, September 27 from 10:30 to 10:55
a.m. at the Sofitel New York. To access the live webcast of
Paratek's Ladenburg Thalmann presentation, please visit
http://wsw.com/webcast/ladenburg2/prtk. A replay of the webcast can
be accessed for up to 90 days following the live presentation.
About ParatekParatek
Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies based
upon its expertise in novel tetracycline chemistry. Paratek's lead
product candidate, omadacycline, is the first in a new class of
tetracyclines known as aminomethylcyclines, with broad-spectrum
activity against Gram-positive, Gram-negative and atypical
bacteria. In June 2016 Paratek announced positive efficacy data in
a Phase 3 registration study in ABSSSI demonstrating the efficacy
and safety of omadacycline compared to linezolid. A Phase 3
registration study for community acquired bacterial pneumonia
(CABP) comparing IV to oral omadacycline to IV to oral moxifloxacin
was initiated in November 2015. Enrollment continues on track to
report top line data, which are expected as early as the third
quarter of 2017. A Phase 3 registration study in ABSSSI comparing
once-daily oral only dosing of omadacycline to twice-daily
oral-only dosing of linezolid was initiated in August 2016. Top
line data are expected as early as the second quarter of 2017. A
phase 1b study in uncomplicated urinary tract infections (UTI) was
initiated in May 2016. Enrollment is nearly complete with top line
data expected as early as the fourth quarter of 2016. Omadacycline
has been granted Qualified Infectious Disease Product designation
and Fast Track status by the U.S. Food and Drug
Administration.Omadacycline is a new once-daily oral and IV,
well-tolerated broad spectrum antibiotic being developed for use as
empiric monotherapy for patients suffering from serious
community-acquired bacterial infections, such as acute bacterial
skin and skin structure infections, community acquired bacterial
pneumonia, urinary tract infections and other community-acquired
bacterial infections, particularly when antibiotic resistance is of
concern to prescribing physicians.Paratek's second Phase 3 product
candidate, sarecycline, is designed to be a well-tolerated,
once-daily, oral, narrow spectrum tetracycline-derived antibiotic
with potent anti-inflammatory properties for the potential
treatment of acne and rosacea in the community setting. Allergan
owns the U.S. rights for the development and commercialization of
sarecycline. Paratek retains all ex-U.S. rights. Allergan initiated
two identical Phase 3 registration studies in December 2014 for
sarecycline for the treatment of moderate to severe acne vulgaris.
Top line data are expected in the first half of 2017. For more
information, visit www.paratekpharma.com.
For more information, visit
www.paratekpharma.com.
CONTACTS:
Media Relations:
Michael Lampe
(484) 575-5040
michael@scientpr.com
Investor Relations:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Sep 2023 to Sep 2024